|
|
|
|
|
by tchalla
1685 days ago
|
|
In 2018 itself, 23andMe had a partnership with GSK > As part of the collaboration, GSK can also change the way we invite patients into clinical trials. The genetic and disease information 23andMe customers share will allow us to identify the kind of patients who are most likely to respond well to new treatments so that 23andMe can invite customers who have consented to be contacted to participate in studies that are relevant to them. This could significantly shorten recruitment and reduce clinical development timelines, allowing some medicines to be delivered to patients faster. https://us.gsk.com/en-us/behind-the-science/innovation/you-m... I'm not sure what the "news" is. |
|
Number of genotyped customers:
Numbers from https://investors.23andme.com/static-files/8db681b8-4ea3-452... (page 11)